Opioid Maker Purdue Asks Judge to Toss Massachusetts Drug Suit
(Bloomberg) -- Purdue Pharma LP says Massachusetts officials are falsely blaming the drug maker for creating the state's opioid epidemic through the marketing of the painkiller Oxycontin.
Massachusetts Attorney General Maura Healey is unfairly vilifying Purdue with “inflammatory'' and “outrageous'' claims, and her lawsuit should be tossed out, the company said in a court filing Monday. Purdue urged the judge to dismiss the case, saying that Healey's allegation of an illegal marketing campaign for Oxycontin won't hold up.
The lawsuit is an example of “oversimplified scapegoating based on a distorted account of the facts unsupported by applicable law,'' Purdue said in the filing.
Jillian Fennimore, a spokeswoman for Healey, said the attorney general intends to oppose Purdue's motion.
Healey originally sued Purdue last year, along with executives and members of the Sackler family that own the company. An unsealed version of the suit showed members of the family deeply involved in efforts to expand the drug's sales.
Richard Sackler, who once served as the privately held firm's president and chairman, embraced a plan to conceal how powerful Oxycontin was in order to boost sales, according to an unsealed deposition. Other filings show the family made more than $4 billion off Oxycontin sales between 2008 and 2015.
Massachusetts is just one of 36 states that have sued Purdue and other opioid makers and distributors who are accused of understating the risks of prescription opioids, overstating their benefits and failing to halt suspiciously large shipments to pharmacies. The companies also face suits from more than 1,500 U.S. cities and counties.
In its dismissal motion, Purdue lawyers note most overdose deaths in Massachusetts are tied to heroin, not prescription drugs, and state officials have noted in the past that most Oxycontin abusers began their addiction problems with alcohol and marijuana.
The state's suit ignores the idea “the opioid-abuse crisis is a complex, multi-factorial societal issue'' that can't be blamed on drug makers alone, Purdue's lawyers noted in the filing.
The case is the Commonwealth of Massachusetts v. Purdue Pharma LP, 1884-cv-01808, Suffolk County Superior Court (Boston).
To contact the reporter on this story: Jef Feeley in Wilmington, Delaware at jfeeley@bloomberg.net
To contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Steve Stroth, Peter Jeffrey
©2019 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.